November 14, 2016 /
Click here to receive MS news via e-mail
rHIgM22 is a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). A second Phase 1 trial in people with MS is currently recruiting patients experiencing an acute relapse. We expect to complete this trial in the first half of 2017.
In April 2015, Acorda presented data from its first Phase 1 clinical trial of rHIgM22. Safety data showed it was well-tolerated in each of the five tested doses, supporting additional clinical development. In addition, testing detected rHIgM22 in cerebrospinal fluid, indicating the drug’s access to the central nervous system. These data were presented at the 67th American Academy of Neurology Annual Meeting.
MS Views and News
Providing educational information, resources and services for those affected by MS
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
